Comparison between radioimmunotherapy and external beam radiation therapy for patients with hepatocellular carcinoma

European Journal of Nuclear Medicine

Volumn 29, Issue 12, 2002, Pages 1657-1668

  Zeng, Zhao Chong ^a   Tang, Zhao You ^a   Yang, Bing Hui ^a   Liu, Kang Da ^a   Wu, Zhi Quan ^a   Fan, Jia ^a   Qin, Lun Xiu ^a   Sun, Hui Chuan ^a   Zhou, Jian ^a   Jiang, Guo Liang ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Lymphocyte subsets; Radiation injuries; Radioimmunotherapy; Radiotherapy

Indexed keywords

ALPHA FETOPROTEIN; FLUOROURACIL; MITOMYCIN C; MONOCLONAL ANTIBODY HEPAMA 1 I 131; MONOCLONAL ANTIBODY I 131; UNCLASSIFIED DRUG; LIVER ENZYME; MONOCLONAL ANTIBODY;

ADULT; AGED; ALLERGIC REACTION; ANIMAL MODEL; ARTERY CATHETER; ARTICLE; ARTIFICIAL EMBOLISM; BEAM THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHILL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAPHORESIS; FEMALE; FEVER; HEPATIC ARTERY LIGATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INCIDENCE; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUSE; NAUSEA; NONHUMAN; PROTEIN BLOOD LEVEL; RADIATION ATTENUATION; RADIATION INJURY; RADIOIMMUNOTHERAPY; SURVIVAL RATE; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; VOMITING; CELL LOSS; CHEMOEMBOLIZATION; ERYTHROCYTE; EXTERNAL BEAM RADIOTHERAPY; MICROSCOPY; ADJUVANT CHEMOTHERAPY; COMPARATIVE STUDY; EVALUATION; HEPATIC ARTERY; LIGATION; LIVER TUMOR; LONGITUDINAL STUDY; METHODOLOGY; MIDDLE AGED; MORTALITY; RADIOTHERAPY; REPRODUCIBILITY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SURVIVAL; VALIDATION STUDY;

ANTIBODIES, MONOCLONAL; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CHEMOTHERAPY, ADJUVANT; FEMALE; HEPATIC ARTERY; HUMANS; LIGATION; LIVER NEOPLASMS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RADIATION INJURIES; RADIOIMMUNOTHERAPY; RADIOTHERAPY; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 1842869238     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-002-0996-x     Document Type: Article

References (41)

1. Nerenstone SR, Ihde DC, Friedman MA. Clinical trials in primary hepatocellular carcinoma: Current status and future directions. Cancer Treat Rev 1988; 15:1-31.
2. Shimamura Y, Gunven P, Takenaka Y, et al. Combined peripheral and central chemoembolization of liver tumors. Experience with Lipiodol-doxorubicin and gelatin sponge (L-TAE). Cancer 1988; 61:238-242.
3. Ngan H, Lai CL, Fan ST, et al. Treatment of inoperable hepatocellular carcinoma by transcatheter arterial chemoembolization using an emulsion of cisplatin in iodized oil and gelfoam. Clin Radiol 1993; 47:315-320.
4. Yu YQ, Xu DB, Zhou XD, et al. Experience with liver resection after hepatic arterial chemoembolization for hepatocellular carcinoma. Cancer 1993; 71:62-65.
5. Zeng ZC, Tang ZY, Wu ZQ, et al. Phase I clinical trial of oral Furtulon and combined hepatic arterial chemoembolization and radiotherapy in unresectable primary liver cancers, including clinicopathologic study. Am J Clin Oncol (CCT) 2000; 23:449-454.
6. Seong J, Keum KC, Han KH, et al. Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 1999; 43:393-397.
7. Cheng JC, Chuang VP, Cheng SH, et al. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2000; 47:435-442.
8. Dawson LA, McGinn CJ, Normolle D, et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 2000; 18:2210-2218.
9. Ishikura S, Ogino T, Furuse J, et al. Radiotherapy after transcatheter arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Clin Oncol 2002; 25:189-193.
10. Tazawa J, Maeda M, Sakai Y, et al. Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement. J Gastroenterol Hepatol 2001; 16:660-665.
11. Balter JM, Lam KL, McGinn CJ, et al. Improvement of CT-based treatment-planning models of abdominal targets using static exhale imaging. Int J Radiat Oncol Biol Phys 1998; 41:939-943.
12. Hall EJ, Cox JD. Physical and biologic basis of radiation therapy. In: Cox JD, eds. Moss' Radiation Oncology, 7th Edn. Philadelphia: Mosby; 1994; 33-35.
13. Fowler JF. Radiobiological aspects of low dose rates in radioimmunotherapy. Int J Radiat Oncol Biol Phys 1990; 18:1261-1269.
14. Knox SJ, Goris ML, Wessels BW. Overview of animal studies comparing radioimmunotherapy with dose equivalent external beam irradiation. Radiother Oncol 1992; 23:111-115.
15. Oi VT, Herzenberg LA. Immunoglobulin producing hybrid cell lines. In: Mishell BB, Shiigi SM, eds. Selected Methods in Cellular Immunology. San Francisco: Freman; 1980:351-372.
16. Xie H, Yang ZH, Chen RM, et al. Two mouse hybridomas secreting monoclonal antibodies against human liver carcinoma and their antibody specificity [English abstract]. Acta Biol Exp Sin 1985; 18:363-373.
17. 131I-anti-HCC mAb. Phase I/II clinical trials. J Cancer Res Clin Oncol 1998; 124:275-280.
18. 131I-labeled Hepama-1 MAb. Preliminary results and discussion. Cancer Immunol Immunother 1994; 39:332-336.
19. Zeng ZC, Tang ZY, Liu KD, et al. Observation of changes in peripheral T-lymphocyte subsets by flow cytometry in patients with liver cancer treated with radioimmunotherapy. Nucl Med Commun 1995; 16:378-385.
20. Tang ZY, Yu YQ, Zhou XD, et al. Treatment of unresectable primary liver cancer with reference to cytoreduction and sequential resection. World J Surg 1995; 19:47-52.
21. Zeng ZC, Tang ZY, Iliakis G, et al. The role of DNA-PK subunits radiosensitization by hyperthermia on hepatocellular carcinoma HepG2 cell line [abstract]. J Gastroenter Hepatol 2000; 15 (Suppl 1):I117.
22. Fisher DR, Hendry JH. Dose fractionation and hepatocyte clonogens: α/β ≈1-2 Gy, and β decreases with increasing delay before assay. Radiat Res 1988; 113:51-57.
23. Tancini G, Barni S, Rescaldani R, et al. Analysis of T helper and suppressor lymphocyte subsets in relation to the clinical stage of solid neoplasms. Oncology 1990; 47:381-384.
24. Yang SJ, Rafla S, Youssef E, et al. Changes in T-cell subsets after radiation therapy. Radiology 1988; 168:537-540.
25. Pillai R, Balaram P, Nair BS, et al. Lymphocyte subset distribution after radiation therapy for cancer of the uterine cervix. Cancer 1991; 67:2071-2078.
26. Stillwagon GB, Order SE, Guse G, et al. Prognostic factors in unresectable hepatocellular cancer: RTOG study 83-01. Int J Radiat Oncol Biol Phys 1991; 20:65-71.
27. Villa E, Moles A, Ferretti I, et al. Natural history of inoperable HCC: Estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology 2000; 32:233-238.
28. Qin LX, Tang ZY. The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol 2002; 8:193-199.
29. Semeniuk DJ, Boismenu R, Tam J, et al. Evidence that immunosuppression is an intrinsic property of the AFP molecule. Adv Exp Med Biol 1995; 383:255-269.
30. Camphausem K, Moses MA, Beecken WD, et al. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res 2001; 61:2207-2211.
31. Sawada N, Ishikawa T, Sekiguchi F, et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of Xeloda in human cancer xenografts. Clin Cancer Res 1999; 5:2948-2953.
32. Kozin SV, Boucher Y, Hicklin DJ, et al. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 2001; 61:39-44.
33. O'Donoghue JA, Sgouros G, Divgi CR, et al. Single-dose versus fractionated radioimmunotherapy: Model comparisons for uniform tumor dosimetry. J Nucl Med 2000; 41:538-547.
34. McIntire KR, Vogel CL, Princler GP, Patel IR. Serum AFP as a biochemical marker for hepatocellular carcinoma. Cancer Res 1972; 32:1941-1946.
35. Trott KR. Cell repopulation and overall treatment time. Int J Radiat Oncol Biol Phys 1990; 19:1071-1075.
36. Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988; 27:131-146.
37. Puck TT, Marcus PI. Action of X-rays on mammalian cells. J Exp Med 1956; 103:653-667.
38. Nagasawa H, Keng P, Harley R, et al. Relationship between gamma-ray-induced G2/M delay and cellular radiosensitivity. Int J Radiat Biol 1994; 66:373-379.
39. Tolmach LJ, Marcus PI. Development of X-ray induced giant Hela cells. Exp Cell Res 1960; 20:350-356.
40. Tim SB, Williams AC, Paraskeva C. Inhibition of radiation-induced G2 delay potentiates cell death by apoptosis and/or the induction of giant cells in colorectal tumor cells with disrupted p53 function. Clin Cancer Res 1997; 3:1371-1381.
41. Asaad NA, Zeng ZC, Guan J, et al. Homologous recombination as a potential target for caffeine radiosensitization in mammalian cells: Reduced caffeine radiosensitization in XRCC2 and CRCC3 mutants. Oncogene 2000; 19:5788-5800.